Myocardial injury detected by T1 and T2 mapping on CMR predicts subsequent cancer therapy-related cardiac dysfunction in patients with breast cancer treated by epirubicin-based chemotherapy or left-sided RT.
Enver TahirManuella AzarSahar ShihadaKatharina SeiffertYvonne GoyAntonia Beitzen-HeinekeIsabel MolwitzKai MuellerleileChristian StehningGerhard SchönGerhard AdamCordula PetersenVolkmar MüllerGunnar K LundPublished in: European radiology (2021)
• Myocardial T1 and T2 relaxation times increased at FU1 after epirubicin-based chemotherapy, but not after left-sided radiotherapy. • Cancer therapy-related cardiac dysfunction (CTRCD) occurred in 20% of patients after epirubicin-based chemotherapy and in 4% after left-sided radiotherapy. • Combined use of increased T1 and reduced LVEF had an AUC of 0.810 (0.695-0.896) to predict CTRCD with good sensitivity (78%, 44-95%) and specificity (84%, 72-92%).
Keyphrases
- locally advanced
- cancer therapy
- left ventricular
- rectal cancer
- end stage renal disease
- drug delivery
- early stage
- newly diagnosed
- radiation therapy
- squamous cell carcinoma
- oxidative stress
- chronic kidney disease
- ejection fraction
- peritoneal dialysis
- high resolution
- radiation induced
- patient reported outcomes
- single molecule
- structural basis